A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

ConditionsCancer Immunotherapy PD-1 PD-L1 Immune Checkpoint Therapy

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorOxford Biodynamics Inc.

About this trial

The purpose of this research is to test whether a blood-based 3D genome conformation mapping test called the Episwitch CiRT® can help to identify likelihood of response to PD-(L)-1 checkpoint inhibitors (a class of cancer drugs) across multiple oncological indications by comparing the results to actual treatment responses for cancer patients.

Eligibility criteria

Qualifiers

18 years of age or older

Stage III or IV cancer

Selected by their healthcare provider to receive the Episwitch CiRT® test according to the current evidence-based schedule (per protocol) as part of their standard of practice.

ECOG performance status ≤ 2

Disqualifiers

Pregnant or breastfeeding

History of bone marrow or organ transplant

Contra indication for receiving Immune Check Point inhibitor.

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Oxford Biodynamics Inc.

Lead sponsor

Community Clinical Oncology Research Network, LLC

Collaborator

Source ClinicalTrials.gov